MVCD7
MCID: MCR120
MIFTS: 48

Microvascular Complications of Diabetes 7 (MVCD7)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 7

MalaCards integrated aliases for Microvascular Complications of Diabetes 7:

Name: Microvascular Complications of Diabetes 7 57 74 29 13 6
Diabetic Nephropathy 74 72
Mvcd7 57 74
Microvascular Complications of Diabetes, Susceptibility to, 7 57
Nonproliferative Retinopathy, Diabetic, Susceptibility to 57
Proliferative Retinopathy, Diabetic, Susceptibility to 57
Microvascular Complications of Diabetes, Type 7 40
Nephropathy, Diabetic, Susceptibility to 57
Nonproliferative Retinopathy, Diabetic 57
Diabetic Non-Proliferative Retinopathy 74
Proliferative Retinopathy, Diabetic 57
Proliferative Diabetic Retinopathy 72
Diabetic Proliferative Retinopathy 74
Nephropathy, Diabetic 57

Classifications:



External Ids:

MeSH 44 D048909
UMLS 72 C0011881 C0154830

Summaries for Microvascular Complications of Diabetes 7

UniProtKB/Swiss-Prot : 74 Microvascular complications of diabetes 7: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 7, also known as diabetic nephropathy, is related to atherosclerosis, premature, with deafness, nephropathy, diabetes mellitus, photomyoclonus, and degenerative neurologic disease and microvascular complications of diabetes 3. An important gene associated with Microvascular Complications of Diabetes 7 is HFE (Homeostatic Iron Regulator). The drugs Pioglitazone and Methylcobalamin have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and pancreas.

More information from OMIM: 612635 PS603933

Related Diseases for Microvascular Complications of Diabetes 7

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 7 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 423)
# Related Disease Score Top Affiliating Genes
1 atherosclerosis, premature, with deafness, nephropathy, diabetes mellitus, photomyoclonus, and degenerative neurologic disease 12.3
2 microvascular complications of diabetes 3 12.1
3 microvascular complications of diabetes 1 12.0
4 microvascular complications of diabetes 2 12.0
5 microvascular complications of diabetes 4 11.9
6 microvascular complications of diabetes 6 11.9
7 diabetic angiopathy 11.6
8 feigenbaum bergeron richardson syndrome 11.3
9 end stage renal failure 10.6
10 fibrosis of extraocular muscles, congenital, 1 10.5
11 hypertension, essential 10.5
12 neuropathy 10.4
13 kidney hypertrophy 10.4
14 kidney disease 10.4
15 hypercholesterolemia, familial, 1 10.3
16 hyperglycemia 10.3
17 atherosclerosis susceptibility 10.3
18 nephrosclerosis 10.3
19 hyperuricemia 10.3
20 diabetic neuropathy 10.3
21 hypoglycemia 10.3
22 proteasome-associated autoinflammatory syndrome 1 10.3
23 yemenite deaf-blind hypopigmentation syndrome 10.3
24 muscle hypertrophy 10.3
25 glucose intolerance 10.3
26 cytokine deficiency 10.3
27 arteries, anomalies of 10.3
28 hyperlipoproteinemia, type iii 10.3
29 coronary artery anomaly 10.3
30 congestive heart failure 10.3
31 cerebrovascular disease 10.3
32 diabetes mellitus 10.3
33 wilms tumor 5 10.3
34 systemic lupus erythematosus 10.2
35 homocysteinemia 10.2
36 focal segmental glomerulosclerosis 10.2
37 creatinine clearance quantitative trait locus 10.2
38 deficiency anemia 10.2
39 lipoid nephrosis 10.2
40 rapidly involuting congenital hemangioma 10.2
41 arterial calcification, generalized, of infancy, 1 10.2
42 eclampsia 10.2
43 b-cell lymphoma 10.2
44 autoimmune disease 10.2
45 wilms tumor 1 10.2
46 body mass index quantitative trait locus 1 10.2
47 coronary heart disease 1 10.2
48 arteriolosclerosis 10.2
49 vasculitis 10.2
50 fatty liver disease 10.2

Comorbidity relations with Microvascular Complications of Diabetes 7 via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Diabetic Cataract Diabetic Polyneuropathy
Heart Disease Hypertension, Essential
Hypoglycemia Microvascular Complications of Diabetes 1
Peripheral Vascular Disease Rubeosis Iridis

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 7:



Diseases related to Microvascular Complications of Diabetes 7

Symptoms & Phenotypes for Microvascular Complications of Diabetes 7

Clinical features from OMIM:

612635

Drugs & Therapeutics for Microvascular Complications of Diabetes 7

Drugs for Microvascular Complications of Diabetes 7 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 431)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
3
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
4
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
5
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
6
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
7
Atenolol Approved Phase 4 29122-68-7 2249
8
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
9
Methyldopa Approved Phase 4 555-30-6 38853
10
Clonidine Approved Phase 4 4205-90-7 2803
11
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
12
Capsaicin Approved Phase 4 404-86-4 1548943
13
Bevacizumab Approved, Investigational Phase 4 216974-75-3
14
Dipivefrin Approved Phase 4 52365-63-6 3105
15
Ranibizumab Approved Phase 4 347396-82-1 459903
16
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
17
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
18
Povidone-iodine Approved Phase 4 25655-41-8
19
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
20
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
21
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
22
Probucol Approved, Investigational Phase 4 23288-49-5 4912
23
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
24
Ramipril Approved Phase 4 87333-19-5 5362129
25
Doxazosin Approved Phase 4 74191-85-8 3157
26
Indapamide Approved Phase 4 26807-65-8 3702
27
Atorvastatin Approved Phase 4 134523-00-5 60823
28
Trandolapril Approved Phase 4 87679-37-6 5484727
29
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
30
Nisoldipine Approved Phase 4 63675-72-9 4499
31
Insulin glargine Approved Phase 4 160337-95-1
32
Insulin glulisine Approved Phase 4 207748-29-6
33
Liraglutide Approved Phase 4 204656-20-2 44147092
34
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
35
Allopurinol Approved Phase 4 315-30-0 2094
36
Nitric Oxide Approved Phase 4 10102-43-9 145068
37
Insulin Lispro Approved Phase 4 133107-64-9
38
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723 149351
39
Glimepiride Approved Phase 4 93479-97-1 3476
40
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
41
Febuxostat Approved Phase 4 144060-53-7 134018
42
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
43
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
44
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
45
Amlodipine Approved Phase 4 88150-42-9 2162
46
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
47
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
48
Terazosin Approved Phase 4 63590-64-7 5401
49
Hydralazine Approved Phase 4 86-54-4 3637
50
Gliclazide Approved Phase 4 21187-98-4 3475

Interventional clinical trials:

(show top 50) (show all 589)
# Name Status NCT ID Phase Drugs
1 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
2 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
3 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
4 Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
5 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
6 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
7 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
8 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
9 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Unknown status NCT03147677 Phase 4 Alfacalcidol;Irbesartan
10 Effects of Glatiramer Acetate (Copaxone) in the Nerve Fiber Layer Thickness and Retinal Function in Diabetic Patients After Pan- Retinal Photocoagulation (PRP), a Double- Masked Randomized Clinical Trial. Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
11 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
12 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
13 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
14 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
15 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
16 A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study Unknown status NCT01306981 Phase 4 Ranibizumab;Saline
17 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
18 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
19 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
20 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
21 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
22 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
23 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Unknown status NCT02690883 Phase 4 Exenatide;Lispro
24 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
25 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
26 A Study on the Anti-proteinuric Effects of Pioglitazone in Patients With Type 2 Diabetes. Unknown status NCT00749047 Phase 4 Pioglitazone
27 Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
28 Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial Unknown status NCT01500590 Phase 4 Renin-angiotensin system blockers;non-renin angiotensin system blockers
29 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
30 The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
31 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
32 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
33 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
34 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
35 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
36 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
37 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
38 Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab. Completed NCT00801866 Phase 4 Bevacizumab
39 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4 Non-ARB (standard therapy);ARB (Telmisartan)
40 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
41 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
42 Effect of Adjunctive Intravitreal Bevacizumab Before Panretinal Photocoagulation in Macular Thickness and Retinal Nerve Fiber Layer Thickness Completed NCT01504724 Phase 4 bevacizumab
43 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
44 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
45 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
46 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
47 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil;Candesartan Cilexetil 32mg
48 A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy Completed NCT00234871 Phase 4 trandolapril/verapamil;Lotrel (amlodipine/benazepril)
49 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
50 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4

Search NIH Clinical Center for Microvascular Complications of Diabetes 7

Inferred drug relations via UMLS 72 / NDF-RT 51 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Genetic Tests for Microvascular Complications of Diabetes 7

Genetic tests related to Microvascular Complications of Diabetes 7:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 7 29 HFE

Anatomical Context for Microvascular Complications of Diabetes 7

MalaCards organs/tissues related to Microvascular Complications of Diabetes 7:

41
Kidney, Endothelial, Pancreas, Bone, Heart, Monocytes, Eye

Publications for Microvascular Complications of Diabetes 7

Articles related to Microvascular Complications of Diabetes 7:

(show top 50) (show all 17321)
# Title Authors PMID Year
1
The HFE gene is associated to an earlier age of onset and to the presence of diabetic nephropathy in diabetes mellitus type 2. 38 8 71
15347835 2004
2
Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. 38 8 71
11423500 2001
3
Prevalence, characteristics, and prognostic significance of HFE gene mutations in type 2 diabetes: the Fremantle Diabetes Study. 8 71
18566337 2008
4
A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes. 8 71
14618419 2003
5
Proliferative retinopathy in a patient with diabetes mellitus and idiopathic haemochromatosis. 8 71
678784 1978
6
Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. 71
19084217 2009
7
Iron-overload-related disease in HFE hereditary hemochromatosis. 71
18504828 2008
8
Iron-overload-related disease in HFE hereditary hemochromatosis. 71
18499578 2008
9
Frequency of the hemochromatosis gene mutations in the population of Serbia and Montenegro. 71
16879202 2006
10
Association of porphyria cutanea tarda with hereditary hemochromatosis. 71
15280838 2004
11
Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. 71
15060098 2004
12
Hemochromatosis mutations in the general population: iron overload progression rate. 71
15070663 2004
13
The 16189 variant of mitochondrial DNA occurs more frequently in C282Y homozygotes with haemochromatosis than those without iron loading. 71
14729817 2004
14
Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis. 71
14673107 2003
15
Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. 71
12915468 2003
16
Hereditary haemochromatosis: only 1% of adult HFEC282Y homozygotes in South Wales have a clinical diagnosis of iron overload. 71
12436244 2002
17
The hemochromatosis protein HFE inhibits iron export from macrophages. 71
12429850 2002
18
Clinical haemochromatosis in HFE mutation carriers. 71
12241803 2002
19
Co-selection of the H63D mutation and the HLA-A29 allele: a new paradigm of linkage disequilibrium? 71
11904676 2002
20
Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. 71
11812557 2002
21
Identification of an endogenous RNA transcribed from the antisense strand of the HFE gene. 71
11532995 2001
22
Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause? 71
11358905 2001
23
Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. 71
10431233 1999
24
Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. 71
10401000 1999
25
The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. 71
10381492 1999
26
Hemochromatosis in Ireland and HFE. 71
9851896 1998
27
Celtic origin of the C282Y mutation of hemochromatosis. 71
9851897 1998
28
The hemochromatosis 845 G-->A and 187 C-->G mutations: prevalence in non-Caucasian populations. 71
9585606 1998
29
Targeted disruption of the HFE gene. 71
9482831 1998
30
Phenotype-genotype correlation in haemochromatosis subjects. 71
9439654 1997
31
Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. 71
9356458 1997
32
A candidate gene for hemochromatosis: frequency of the C282Y and H63D mutations. 71
9341868 1997
33
The significance of the 187G (H63D) mutation in hemochromatosis. 71
9326341 1997
34
Homozygosity for the predominant Cys282Tyr mutation and absence of disease expression in hereditary haemochromatosis. 71
9321765 1997
35
The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. 71
9162021 1997
36
Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. 71
9106528 1997
37
Global prevalence of putative haemochromatosis mutations. 71
9138148 1997
38
Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. 71
9024376 1997
39
Absence of the hemochromatosis gene Cys282Tyr mutation in three ethnic groups from Algeria (Mzab), Ethiopia, and Senegal. 71
9211748 1997
40
Haemochromatosis and HLA-H. 71
8896549 1996
41
Haemochromatosis and HLA-H. 71
8896550 1996
42
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. 71
8696333 1996
43
Silence of lncRNA GAS5 alleviates high glucose toxicity to human renal tubular epithelial HK-2 cells through regulation of miR-27a. 38
31159592 2019
44
Association of the polymorphisms in FOXO1 gene and diabetic nephropathy risk. 38
30987438 2019
45
Knockdown of ANGPTL-4 inhibits inflammatory response and extracellular matrix accumulation in glomerular mesangial cells cultured under high glucose condition. 38
31387395 2019
46
Arbutin protects HK-2 cells against high glucose-induced apoptosis and autophagy by up-regulating microRNA-27a. 38
31319730 2019
47
miR-15b-5p ameliorated high glucose-induced podocyte injury through repressing apoptosis, oxidative stress, and inflammatory responses by targeting Sema3A. 38
31025335 2019
48
Epidemiology investigation and analysis of patients with hemodialysis in Sichuan province of China. 38
31296088 2019
49
Effects of autophagy on macrophage adhesion and migration in diabetic nephropathy. 38
31352855 2019
50
Diagnostic value of neutrophil gelatinase-associated lipocalin in diabetic nephropathy: a meta-analysis. 38
31215304 2019

Variations for Microvascular Complications of Diabetes 7

ClinVar genetic disease variations for Microvascular Complications of Diabetes 7:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 HFE NM_000410.3(HFE): c.187C> G (p.His63Asp) single nucleotide variant Pathogenic rs1799945 6:26091179-26091179 6:26090951-26090951
2 HFE NM_000410.3(HFE): c.845G> A (p.Cys282Tyr) single nucleotide variant Conflicting interpretations of pathogenicity, other rs1800562 6:26093141-26093141 6:26092913-26092913
3 HFE NM_000410.3(HFE): c.193A> T (p.Ser65Cys) single nucleotide variant Uncertain significance rs1800730 6:26091185-26091185 6:26090957-26090957

Expression for Microvascular Complications of Diabetes 7

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 7.

Pathways for Microvascular Complications of Diabetes 7

GO Terms for Microvascular Complications of Diabetes 7

Sources for Microvascular Complications of Diabetes 7

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....